You are viewing: Europe Cancer Diagnostics Market analysis
Part of: Cancer Diagnostics Market (Global)

The Europe Cancer Diagnostics Market was valued at $4234.3 Million in 2021 and projected to reach to $7333.8 Million by 2026, representing a compound annual growth rate of 11.6%. Europe's cancer diagnostics market is poised for sustained expansion through 2026, supported by increasing healthcare expenditures, aging demographics, and widespread adoption of advanced diagnostic technologies.

Europe Cancer Diagnostics Market (2021-2026) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Cancer Diagnostics Market Trends and Insights

  • This expansion reflects Europe's aging population, increased cancer prevalence, and rising healthcare investments across the region.
  • Europe maintains advanced diagnostic infrastructure and regulatory frameworks that support innovation in molecular, imaging, and laboratory-based cancer detection technologies. The European market benefits from strong healthcare systems, high awareness of early cancer detection, and substantial R&D spending by both public and private sectors.
  • Europe's 11.6% compound annual growth rate (CAGR) from 2021 to 2026 underscores growing demand for precision diagnostics and personalized medicine approaches.
  • Key European markets, including Germany, France, and the United Kingdom, are driving adoption of next-generation sequencing, liquid biopsy, and AI-enabled diagnostic platforms that enhance clinical outcomes and patient stratification..

Key Market Statistics

  • CAGR (2021-2026) 11.6% CAGR
  • Market Size, 2021 ~USD 4234.3 Million
  • Forecast, 2026 ~USD 7333.8 Million
  • Geography Europe

Europe Cancer Diagnostics Market Overview

Strong Regional Growth Trajectory :

Europe's cancer diagnostics market is expanding at a CAGR of 11.6%, outpacing global growth of 11.5%, driven by advanced healthcare infrastructure and increasing diagnostic adoption across member states.

Aging Population Driving Demand :

Europe's demographic shift toward an older population has significantly increased cancer prevalence, creating sustained demand for innovative diagnostic solutions and early detection technologies.

Regulatory Excellence and Innovation :

Stringent EU regulatory frameworks and CE marking requirements ensure high-quality diagnostic products, fostering innovation while maintaining patient safety standards across the region.

Substantial Market Expansion :

The market is projected to grow from $4,234.3 million in 2021 to $7,333.8 million by 2026, representing a 73% increase driven by healthcare investments and technological advancement.

Europe Cancer Diagnostics Market Dynamics

  • The region's mature healthcare systems and strong regulatory environment create favorable conditions for market players to introduce innovative solutions.
  • Key growth drivers include rising cancer incidence rates, improved reimbursement policies, and growing emphasis on early detection and personalized medicine across European healthcare systems. The competitive landscape in Europe remains dynamic, with both established diagnostic companies and emerging innovators investing heavily in research and development.
  • Collaborations between healthcare institutions, government initiatives promoting cancer screening programs, and integration of artificial intelligence in diagnostics are expected to accelerate market growth.
  • Regional variations in healthcare spending and diagnostic adoption rates present both opportunities and challenges for market participants seeking to expand their European footprint..

Market Ecosystem

logo-mobile

CANCER DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Develops molecular and tissue-based cancer diagnostic solutions, including companion diagnostics, PCR-based assays, next-generation sequencing (NGS), immunohistochemistry (IHC), and digital pathology for oncology applications. Enables early and accurate cancer detection, supports personalized treatment selection, improves diagnostic confidence, and enhances patient outcomes through precision medicine.
company logo
Develops advanced cancer diagnostic solutions, including molecular diagnostics, HPV testing, cervical cytology, breast imaging (3D mammography/tomosynthesis), biopsy systems, and digital pathology technologies for early cancer detection, diagnosis, and treatment guidance. Enables early and accurate cancer detection, improves screening and diagnostic accuracy, supports personalized treatment decisions, enhances workflow efficiency, and improves patient outcomes through comprehensive oncology diagnostics.
company logo
Provides molecular oncology testing, digital pathology, tissue diagnostics, flow cytometry, and NGS solutions for detecting cancer biomarkers, monitoring disease progression, and guiding targeted therapies. Delivers rapid and precise cancer diagnosis, improves laboratory efficiency, supports personalized oncology care, and enables informed treatment decisions.
company logo
Provides advanced imaging technologies, laboratory diagnostics, molecular testing, and AI-enabled solutions for cancer screening, diagnosis, staging, and therapy monitoring. Enhances early cancer detection, improves diagnostic precision, supports treatment planning, and streamlines oncology workflows.
company logo
Develops molecular diagnostic kits, sample preparation technologies, companion diagnostics, and NGS workflows for identifying cancer-related genetic mutations and biomarkers. Enables accurate biomarker detection, supports precision oncology, accelerates molecular testing, and improves patient stratification for targeted therapies.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • CONMED Corporation

      Key Takeaways

      • Europe's cancer diagnostics market is projected to grow from $4,234.3 million in 2021 to $7,333.8 million by 2026, representing a 11.6% CAGR.
      • Europe's advanced healthcare infrastructure and regulatory environment accelerate adoption of innovative diagnostic technologies including molecular and imaging-based solutions.
      • Rising cancer incidence and aging demographics across Europe drive demand for early detection and precision diagnostic tools.
      • Europe's strong R&D ecosystem and reimbursement policies support commercialization of next-generation sequencing, liquid biopsy, and AI-powered diagnostic platforms.

      Cancer Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2021
      Fastest Growing Segment BREAST CANCER (Application)
      Forecast Period 2021-2026
      Growth Rate CAGR of 11.5% from 2021 to 2026
      Largest Segment HOSPITALS (End User)
      Market Size Base Year (Billions) ~USD 15.44 (2021)
      Revenue Forecast (Billions) ~USD 26.6 (2026)
      Segments Covered Product, Type, Technology, Application, End User

      Europe Cancer Diagnostics Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Consumables
      • Instruments

      By Type

      • Antibodies
      • Biopsy Instruments
      • Cell Processors
      • Ct
      • Ct Systems
      • Flow Cytometry
      • Ihc
      • Imaging Instruments
      • Immunoassay
      • Ish
      • Kits & Reagents
      • Mammography
      • Mammography Systems
      • Microarray
      • Microarrays
      • Microarrays Instruments
      • Mri
      • Mri Systems
      • Ngs
      • Ngs Instruments
      • Nuclear Imaging
      • Nuclear Imaging Systems
      • Other Consumables
      • Other Ivd Technologies
      • Other Pathology-Based Instruments
      • Pathology-Based Instruments
      • Pcr
      • Pcr Instruments
      • Probes
      • Slide Staining Systems
      • Tissue Processing Systems
      • Ultrasound
      • Ultrasound Systems

      By Technology

      • Biopsies
      • Imaging Technologies
      • Ivd Testing

      By Application

      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Melanoma
      • Other Cancers

      By End User

      • Diagnostic Laboratories
      • Hospitals

      Target Audience

      • Diagnostic Device Manufacturers : Manufacturers need Europe-specific market data to develop localized product strategies, navigate regulatory requirements, and identify optimal market entry points across diverse European healthcare systems.
      • Healthcare Investors and PE Firms : Investment professionals require detailed European market forecasts and country-level insights to evaluate acquisition targets, assess growth potential, and make informed capital allocation decisions.
      • Hospital and Laboratory Networks : Healthcare providers need market intelligence on emerging diagnostic technologies, competitive offerings, and procurement trends to optimize diagnostic capabilities and improve patient outcomes.
      • Pharmaceutical and Biotech Companies : Companies developing cancer therapeutics require companion diagnostic market data to understand testing infrastructure, reimbursement landscapes, and integration opportunities across European markets.
      • Healthcare Consultants and Advisors : Consulting firms advising healthcare clients need comprehensive European market analysis to support strategic planning, market entry strategies, and competitive positioning recommendations.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 11789.2 Million · 10.5% wtd CAGR ·
      Asia Pacific
      ~USD 7200.7 Million · 14.1% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      UKUSD 860.6 Million
      GermanyUSD 1410.7 Million
      FranceUSD 735.2 Million
      ItalyUSD 613.8 Million
      SpainUSD 427.8 Million
      Rest Of EuropeUSD 3285.7 Million

      Country market size visualization

      UK
      USD 860.6 Million
      Germany
      USD 1410.7 Million
      France
      USD 735.2 Million
      Italy
      USD 613.8 Million
      Spain
      USD 427.8 Million
      Rest Of Europe
      USD 3285.7 Million

      Reasons to Buy this Report

      • Country-Level Market Breakdown : Access detailed market sizing for major European economies including Germany, UK, France, Italy, and Spain, enabling precise market entry strategies and competitive positioning.
      • Regulatory and Compliance Insights : Understand EU regulatory frameworks, CE marking requirements, and country-specific compliance standards essential for product launches and market expansion across Europe.
      • Growth Opportunity Identification : Identify high-growth segments and underserved markets within Europe's cancer diagnostics landscape, with forecasts through 2026 to guide investment and R&D prioritization.
      • Competitive Landscape Analysis : Benchmark against regional competitors and understand market dynamics specific to Europe, including pricing strategies, distribution channels, and partnership opportunities.
      • Strategic Market Intelligence : Leverage comprehensive data on aging populations, healthcare spending trends, and diagnostic adoption rates to inform business strategy and resource allocation decisions.

      Frequently asked questions

      What is the projected size of Europe's cancer diagnostics market by 2026?

      Europe's cancer diagnostics market is projected to reach $7,333.8 million by 2026, growing from $4,234.3 million in 2021 at an 11.6% CAGR.

      What factors are driving growth in Europe's cancer diagnostics market?

      Europe's market growth is driven by aging populations, increased cancer prevalence, advanced healthcare infrastructure, strong R&D investment, and rising adoption of precision diagnostic technologies.

      Which diagnostic technologies are gaining traction in Europe?

      Europe is experiencing increased adoption of next-generation sequencing, liquid biopsy, AI-enabled diagnostics, molecular profiling, and advanced imaging technologies for cancer detection and stratification.

      How does Europe's cancer diagnostics market compare to global trends?

      Europe's 11.6% CAGR from 2021 to 2026 is slightly higher than the global 11.5% CAGR, reflecting Europe's mature healthcare systems and strong diagnostic innovation ecosystem.

      Which European countries are leading the cancer diagnostics market?

      Germany, France, and the United Kingdom are among Europe's largest markets, driven by advanced healthcare systems, high diagnostic adoption rates, and substantial healthcare spending.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the Cancer Diagnostics  market. Exhaustive secondary research was done to collect information on the Cancer Diagnostics  market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Cancer Diagnostics  market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, Factiva, whitepapers, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the Cancer Diagnostics  market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors and Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Cancer Diagnostics  Market Related Personnel from various companies and organizations operating in the Cancer Diagnostics  market. Primary sources from the demand side included Law Enforcement Agencies Vice Presidents,C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Team of Hospitals, Clinic Personnel, and Laboratory Technicians.

      Breakdown of Primary Interviews

      Cancer Diagnostics Market Size, and Share

      Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
      Note 2: Other primaries include sales, marketing, and product managers.
      Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the Cancer Diagnostics  market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Cancer Diagnostics Market : Top-Down and Bottom-Up Approach

      Cancer Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at precise statistics for all segments.

      Approach to derive the market size and estimate market growth.

      Using secondary data from paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of Cancer Diagnostics . Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.

      Market Definition

      Cancer diagnostics refers to the tests, technologies, and procedures used to detect, diagnose, characterize, and monitor cancer, enabling early detection, accurate diagnosis, treatment selection, and disease monitoring. The market includes imaging, molecular diagnostics, biopsy-based testing, immunohistochemistry (IHC), next-generation sequencing (NGS), liquid biopsy, and companion diagnostics, serving hospitals, diagnostic laboratories, cancer centers, and research institutes.

      Key Stakeholders

      • Diagnostic test and kit manufacturers
      • Medical device and imaging equipment manufacturers
      • Molecular diagnostics and genomics companies
      • Hospitals and healthcare systems
      • Diagnostic laboratories (clinical and reference laboratories)
      • Cancer centers and oncology clinics
      • Physicians (oncologists, pathologists, radiologists, and primary care physicians)
      • Academic and research institutes
      • Pharmaceutical and biotechnology companies (companion diagnostics and precision medicine)
      • Contract research organizations (CROs)
      • Government and public health agencies
      • Regulatory authorities
      • Health insurance providers and payers
      • Patients and patient advocacy organizations
      • Distributors and healthcare suppliers

      Report Objectives

      • To describe, analyze, and forecast the Cancer Diagnostics  market, by product, type, application, technology, end user, and region.
      • To describe and forecast the Cancer Diagnostics  market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East and Africa
      • To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the Cancer Diagnostics  market
      • To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
      • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
      • To profile key players and comprehensively analyze their market shares and core competencies2 in the Cancer Diagnostics  market
      • To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the Cancer Diagnostics  market

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

      Company Information

      • Detailed analysis and profiling of additional market players (up to 5)

      Product Analysis

      • Product matrix, which gives a detailed comparison of the product portfolios of each company

      Geographic Analysis

      • Further breakdown of the Rest of Asia Pacific Cancer Diagnostics  market into Vietnam, New Zealand, and others.
      • Further breakdown of the Rest of Latin America Cancer Diagnostics  market into Columbia, Chile, Ecuador, and others.
      • Further breakdown of the Rest of Europe Cancer Diagnostics  market into Belgium, Russia, Netherlands, Switzerland, and others.
       

       

      Get the Full Cancer Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Cancer Diagnostics Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status